Ivabradine for Rate Control in Permanent Atrial Fibrillation
Status:
Completed
Trial end date:
2019-09-17
Target enrollment:
Participant gender:
Summary
Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative
effects on hemodynamics and inotropy. The objective in this proof of concept study is to
investigate the hypothesis that ivabradine will slow the ventricular response in patients
with permanent atrial fibrillation and previously-implanted pacemakers.